Switch theme
Sign up to access all valuation multiples
Formycon AG is a pharmaceutical company. It is engaged in the development of pharmaceutical and biopharmaceutical products and the development of drug delivery systems. Its focus is on treatments in ophthalmology and immunology as well as other chronic diseases. The company's pipeline in the biosimilar drugs category includes FYB201, FYB202, FYB203, and FYB207 for the treatment of COVID-19. It is also engaged in the provision of diagnostic laboratory services and works for third parties and the carrying out of diagnostic laboratory services.
2010
250
LTM Revenue $69.7M
LTM EBITDA -$17.3M
$377M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Formycon has a last 12-month revenue of $69.7M and a last 12-month EBITDA of -$17.3M.
In the most recent fiscal year, Formycon achieved revenue of $74.8M and an EBITDA of -$4.4M.
Formycon expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Formycon valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $83.5M | $74.8M | XXX | XXX | XXX |
| Gross Profit | $45.3M | $25.0M | XXX | XXX | XXX |
| Gross Margin | 54% | 33% | XXX | XXX | XXX |
| EBITDA | $87.0M | -$4.4M | XXX | XXX | XXX |
| EBITDA Margin | 104% | -6% | XXX | XXX | XXX |
| Net Profit | $38.7M | $81.4M | XXX | XXX | XXX |
| Net Margin | 46% | 109% | XXX | XXX | XXX |
| Net Debt | $11.8M | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Formycon's stock price is EUR 22 (or $23).
Formycon has current market cap of EUR 382M (or $411M), and EV of EUR 351M (or $377M).
See Formycon trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $377M | $411M | XXX | XXX | XXX | XXX | $-6.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Formycon has market cap of $411M and EV of $377M.
Formycon's trades at 5.4x LTM EV/Revenue multiple, and -21.8x LTM EBITDA.
Analysts estimate Formycon's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Formycon and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $377M | XXX | XXX | XXX |
| EV/Revenue | 5.0x | XXX | XXX | XXX |
| EV/EBITDA | -85.7x | XXX | XXX | XXX |
| P/E | -3.0x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -6.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpFormycon's NTM/LTM revenue growth is 10%
Formycon's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Formycon's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Formycon's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Formycon and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -10% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -6% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -105% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 4% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 29% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 24% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 55% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Formycon acquired XXX companies to date.
Last acquisition by Formycon was XXXXXXXX, XXXXX XXXXX XXXXXX . Formycon acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Formycon founded? | Formycon was founded in 2010. |
| Where is Formycon headquartered? | Formycon is headquartered in Germany. |
| How many employees does Formycon have? | As of today, Formycon has 250 employees. |
| Is Formycon publicy listed? | Yes, Formycon is a public company listed on ETR. |
| What is the stock symbol of Formycon? | Formycon trades under FYB ticker. |
| When did Formycon go public? | Formycon went public in 2010. |
| Who are competitors of Formycon? | Similar companies to Formycon include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Formycon? | Formycon's current market cap is $411M |
| What is the current revenue of Formycon? | Formycon's last 12-month revenue is $69.7M. |
| What is the current EBITDA of Formycon? | Formycon's last 12-month EBITDA is -$17.3M. |
| What is the current EV/Revenue multiple of Formycon? | Current revenue multiple of Formycon is 5.4x. |
| What is the current EV/EBITDA multiple of Formycon? | Current EBITDA multiple of Formycon is -21.8x. |
| What is the current revenue growth of Formycon? | Formycon revenue growth between 2023 and 2024 was -10%. |
| Is Formycon profitable? | Yes, Formycon is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
